Antimicrobial compositions comprising single domain antibodies and pseudomonas exotoxin

US10010625B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-10010625-B2
Application numberUS-201515108380-A
CountryUS
Kind codeB2
Filing dateJan 2, 2015
Priority dateJan 2, 2014
Publication dateJul 3, 2018
Grant dateJul 3, 2018

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The present invention provides heavy chain immunoglobulins of the VHH type or fragment thereof having affinity for a target antigen of interest, including glycoprotein D2 (gD2) of HSV-2 or antigen thereof, and for envelope proteins of HIV-1 or an antigen thereof linked to Pseudomonas exotoxin A or functional fragments thereof. Also included are multimeric forms of the immunoglobulins and their use in the prevention and/or treatment of HSV2 and/or HIV-1.

First claim

Opening claim text (preview).

The invention claimed is: 1. A heavy chain immunoglobulin of the VHH type or fragment thereof comprising an amino acid sequence of at least 85% identity to SEQ ID NO: 7, and having affinity for envelope proteins of HIV-1. 2. A heavy chain immunoglobulin of the VHH type or fragment thereof comprising an amino acid sequence of at least 85% identity to SEQ ID NO: 8, and having affinity for envelope proteins of HIV-1, which is covalently linked to the P. aeruginosa Exotoxin A subunit. 3. The heavy chain immunoglobulin of the VHH type or fragment thereof of claim 2 , having an amino acid sequence of at least 90% identity to SEQ ID NO: 8. 4. A multimeric molecule comprising a heavy chain immunoglobulin fragment of the VHH type according to claim 2 , in which VHH sequences are fused to yield multimeric units of 2 or more VHH units optionally linked via a spacer molecule. 5. A multimeric molecule comprising two or more VHH sequences according to claim 2 , which are fused to yield 2, 3, 4 or 5 or more VHH units optionally linked via a spacer molecule. 6. A nucleic acid encoding a heavy chain immunoglobulin fragment of the VHH type according to claim 1 . 7. An expression vector comprising the nucleic acid encoding a heavy chain immunoglobulin fragment of the VHH type according to claim 1 . 8. The expression vector of claim 6 comprising the nucleic acid sequence of SEQ ID NO: 6. 9. A micro-organism transformed with the expression vector of claim 8 . 10. A micro-organism according to claim 9 , wherein the micro-organism is Lactobacillus. 11. The micro-organism according to claim 10 , selected from the group consisting of L. jensenii, L. reuteri, L. gasseri, L. crispatus , and L. iners. 12. A method for treatment of an HIV-1 infection in a subject, comprising administering to the subject a heavy chain immunoglobulin or fragment thereof of claim 1 . 13. A method for treatment of an HIV-1 infection in a subject, comprising administering to subject a micro-organism of claim 9 expressing the heavy chain immunoglobulin or fragment of claim 1 . 14. A heavy chain immunoglobulin of the VHH type or fragment thereof comprising an amino acid sequence of at least 85% identity to SEQ ID NO: 11, and having affinity for envelope proteins of HIV-1. 15. A heavy chain immunoglobulin of the VHH type or fragment thereof comprising an amino acid sequence of at least 85% identity to SEQ ID NO: 12, and having affinity for envelope proteins of HIV-1, which is covalently linked to the P. aeruginosa Exotoxin A subunit. 16. The heavy chain immunoglobulin of the VHH type or fragment thereof of claim 15 , having an amino acid sequence of at least 90% identity to SEQ ID NO: 12. 17. A method for treatment of an HIV-1 infection in a subject, comprising administering to the subject the multimeric molecule of claim 4 . 18. A method for treatment of an HIV-1 infection in a subject, comprising administering to subject a micro-organism of claim 11 expressing the multimeric molecule of claim 5 .

Assignees

Inventors

Classifications

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US10010625B2 cover?
The present invention provides heavy chain immunoglobulins of the VHH type or fragment thereof having affinity for a target antigen of interest, including glycoprotein D2 (gD2) of HSV-2 or antigen thereof, and for envelope proteins of HIV-1 or an antigen thereof linked to Pseudomonas exotoxin A or functional fragments thereof. Also included are multimeric forms of the immunoglobulins and thei…
Who is the assignee on this patent?
Univ Johns Hopkins
What technology area does this patent fall under?
Primary CPC classification C07K14/21. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue Jul 03 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).